Parenteral use of medium-chain triglycerides: A reappraisal

• Published in: Nutrition (Burbank, Los Angeles County, Calif.) Vol. 12; no. 4; pp. 231 - 238
• Main Authors: Ulrich, Harry, Pastores, Stephen Mccarthy, Katz, David P., Kvetan, Vladimir
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.04.1996; Elsevier
• Subjects: Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Animals; Biological and medical sciences; Critical Illness - therapy; Emergency and intensive care: metabolism and nutrition disorders. Enteral and parenteral nutrition; Fat Emulsions, Intravenous - administration & dosage; Fat Emulsions, Intravenous - chemistry; Fat Emulsions, Intravenous - metabolism; Humans; Intensive care medicine; Liver Diseases - therapy; Medical sciences; Nitrogen - metabolism; Parenteral Nutrition - methods; Parenteral Nutrition, Total - methods; Respiratory Insufficiency - therapy; Sepsis - therapy; Triglycerides - administration & dosage; Triglycerides - chemistry; Triglycerides - metabolism; Human; Intravenous administration; Animal; Fat emulsion; Lipids; Review; Medium chain; Triglyceride; Fatty acids; Parenteral administration; Feeding
• ISSN: 0899-9007; 1873-1244
• DOI: 10.1016/S0899-9007(96)00089-6

Over the last two decades, the clinical use of intravenous fat emulsions for the nutritional support of hospitalized patients has become routine. During this time long-chain triglycerides (LCT) derived from soybean and/or safflower oils were the exclusive lipid source for these emulsions, providing both a safe calorically dense alternative to dextrose and essential fatty acids needed for biologic membranes and the maintenance of immune function. During the past decade, the availability of novel experimental triglycerides for parenteral use has generated interest in the use of these substrates for nutritional and metabolic support. Medium-chain triglycerides (MCT), long advocated as a superior substrate for parenteral use, possess many unique physiochemical and metabolic properties that make them theoretically advantageous over their LCT counterparts. Although not yet approved in the United States, preparations containing MCT have been widely available in Europe. Intravenous MCT preparations, either as physical mixtures or structured lipids, have been used clinically in patients with immunosuppresion, critical illness, liver and pulmonary disease and in premature infants. Despite great promise, the clinical data comparing the efficacy of MCT-based lipid emulsions to their LCT counterparts has been equivocal. This may be due in part to the limited nature of the published clinical trials. Measures of efficacy for parenteral or enteral nutritional products has taken on new meaning, in light of the reported experience using immunomodulatory nutrients. Current concerns about cost of medical care and resource use warrant careful deliberation about the utility of any new and expensive therapy. Until clinical data can fulfill expectations derived from animal studies, it is difficult to advocate the general use of MCT-based lipid emulsions. Future clinical studies with MCT-based emulsions should have clear outcome objectives sufficient to prove their theorized metabolic superiority.